<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD02670000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P02768</UniProt_ID>
  <Seq_Length>609</Seq_Length>
  <Molecule_Weight>69367</Molecule_Weight>
  <KEGG_ID>hsa:213</KEGG_ID>
  <Orthology_ID>K16141</Orthology_ID>
  <Function_Summary>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</Function_Summary>
  <Pfam_ID>PF00273:Serum_albumin</Pfam_ID>
  <Allosteric_Activator_Count>1</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>12</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>4</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Growth-inhibiting protein 20</Alias>
      <Alias>Cell growth inhibiting protein 42</Alias>
      <Alias>SA</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a chaperone protein, a class of proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport.</Detail>
      <Keyword>Chaperone binding</Keyword>
      <Ontology_ID>GO:0051087</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with copper (Cu) ions.</Detail>
      <Keyword>Copper ion binding</Keyword>
      <Ontology_ID>GO:0005507</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a toxin, a poisonous substance that causes damage to biological systems. Toxins are differentiated from simple chemical poisons and vegetable alkaloids by their high molecular weight and antigenicity (they elicit an antibody response).</Detail>
      <Keyword>Toxin binding</Keyword>
      <Ontology_ID>GO:0015643</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a drug, any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.</Detail>
      <Keyword>Drug binding</Keyword>
      <Ontology_ID>GO:0008144</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Inhibition of the reactions brought about by dioxygen (O2) or peroxides. Usually the antioxidant is effective because it can itself be more easily oxidized than the substance protected. The term is often applied to components that can trap free radicals, thereby breaking the chain reaction that normally leads to extensive biological damage.</Detail>
      <Keyword>Antioxidant activity</Keyword>
      <Ontology_ID>GO:0016209</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with pyridoxal 5' phosphate, 3-hydroxy-5-(hydroxymethyl)-2-methyl4-pyridine carboxaldehyde 5' phosphate, the biologically active form of vitamin B6.</Detail>
      <Keyword>Pyridoxal phosphate binding</Keyword>
      <Ontology_ID>GO:0030170</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.</Detail>
      <Keyword>Fatty acid binding</Keyword>
      <Ontology_ID>GO:0005504</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a lipid.</Detail>
      <Keyword>Lipid binding</Keyword>
      <Ontology_ID>GO:0008289</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>587</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>378</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>594</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>138</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>152</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>434</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>574</Position>
      <Original>Asp</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>215</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>292</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>215</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>525</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>338</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>503</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>242</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>25</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>23</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>490</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>264</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>396</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>87</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>84</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>399</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>560</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>146</Position>
      <Original>Val</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>121</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>400</Position>
      <Original>Glu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>389</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>24</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>242</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>357</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>529</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>574</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>338</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>400</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>557</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>337</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>565</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>106</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>73</Position>
      <Original>Phe</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>24</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>24</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>201</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>344</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>406</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>143</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>518</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>584</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>90</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>389</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>420</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>383</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>293</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>220</Position>
      <Original>Gln</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>598</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>23</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>300</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>589</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>27</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>249</Position>
      <Original>Lys</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>27</Position>
      <Original>His</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>345</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>382</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>597</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Bile acid and bile salt transport</Keyword>
      <Ontology_ID>GO:0015721</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of nourishment.</Detail>
      <Keyword>Cellular response to starvation</Keyword>
      <Ontology_ID>GO:0009267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a solute is transported from one side of a membrane to the other.</Detail>
      <Keyword>Transmembrane transport</Keyword>
      <Ontology_ID>GO:0055085</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.</Detail>
      <Keyword>Lipoprotein metabolic process</Keyword>
      <Ontology_ID>GO:0042157</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed, sodium-independent, movement of organic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Sodium-independent organic anion transport</Keyword>
      <Ontology_ID>GO:0043252</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving bile acids, any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.</Detail>
      <Keyword>Bile acid metabolic process</Keyword>
      <Ontology_ID>GO:0008206</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cytolytic destruction of red blood cells, with the release of intracellular hemoglobin, in the host organism by a symbiont. The host is defined as the larger of the organisms involved in a symbiotic interaction.</Detail>
      <Keyword>Hemolysis by symbiont of host erythrocytes</Keyword>
      <Ontology_ID>GO:0019836</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which a mitochondrion is maintained in a specific location within a cell and prevented from moving elsewhere.</Detail>
      <Keyword>Maintenance of mitochondrion location</Keyword>
      <Ontology_ID>GO:0051659</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>294</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>108</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>444</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>297</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>82</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>443</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>164</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>446</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL</Protein_Seq>
    <DNA_Seq>ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGTGTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAAGAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTTGAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGATGAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACAGTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCTGAGAGTAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTGAGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAAAAATACCTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTCTTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCCTGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAGAGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTAGCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACAGATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGACAGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAGGAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGATGAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGCAAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGAAGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACTCTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAATTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAGCAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCCCAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAATGTTGTAAACATCCTGGAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTCCTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGCTGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACATACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTTTCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTTGTGAAACACAAGCCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAGAAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTTGCTGCAAGTCAAGCTGCCTTAGGCTTATAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ALB</Gene_Name>
    <Gene_ID>213</Gene_ID>
    <Genbank_ACCN>NM_000477</Genbank_ACCN>
    <Protein_ACCN>NP_000468</Protein_ACCN>
    <HGNC_ID>399</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/213</Gene_URL>
    <UCSC_ID>uc003hgs.4</UCSC_ID>
    <EMBL_ID>ENSG00000163631</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Gastroenteritis</Disease_Name>
      <Disease_Detail>Gastroenteritis</Disease_Detail>
      <Disease_DB>GST045</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastroenteritis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Drug-Induced Hepatitis</Disease_Name>
      <Disease_Detail>Drug-Induced Hepatitis</Disease_Detail>
      <Disease_DB>DRG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/drug_induced_hepatitis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarin Resistance</Disease_Name>
      <Disease_Detail>Warfarin Resistance</Disease_Detail>
      <Disease_DB>WRF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarin_resistance?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Peritonitis</Disease_Name>
      <Disease_Detail>Peritonitis</Disease_Detail>
      <Disease_DB>PRT036</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/peritonitis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2_diabetes_mellitus?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pyelonephritis</Disease_Name>
      <Disease_Detail>Pyelonephritis</Disease_Detail>
      <Disease_DB>PYL005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pyelonephritis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Blastomycosis</Disease_Name>
      <Disease_Detail>Blastomycosis</Disease_Detail>
      <Disease_DB>BLS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/blastomycosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Renovascular Hypertension</Disease_Name>
      <Disease_Detail>Renovascular Hypertension</Disease_Detail>
      <Disease_DB>RNV001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/renovascular_hypertension?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kwashiorkor</Disease_Name>
      <Disease_Detail>Kwashiorkor</Disease_Detail>
      <Disease_DB>KWS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kwashiorkor?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Viral Pneumonia</Disease_Name>
      <Disease_Detail>Viral Pneumonia</Disease_Detail>
      <Disease_DB>VRL005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/viral_pneumonia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Non-Immune Hydrops Fetalis</Disease_Name>
      <Disease_Detail>Non-Immune Hydrops Fetalis</Disease_Detail>
      <Disease_DB>NNM005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/non_immune_hydrops_fetalis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Esophageal Varix</Disease_Name>
      <Disease_Detail>Esophageal Varix</Disease_Detail>
      <Disease_DB>ESP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/esophageal_varix?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adrenocorticotropic Hormone Deficiency</Disease_Name>
      <Disease_Detail>Adrenocorticotropic Hormone Deficiency</Disease_Detail>
      <Disease_DB>ADR021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adrenocorticotropic_hormone_deficiency?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bacteriuria</Disease_Name>
      <Disease_Detail>Bacteriuria</Disease_Detail>
      <Disease_DB>BCT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bacteriuria?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypersplenism</Disease_Name>
      <Disease_Detail>Hypersplenism</Disease_Detail>
      <Disease_DB>HYP063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypersplenism?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gallbladder Disease</Disease_Name>
      <Disease_Detail>Gallbladder Disease</Disease_Detail>
      <Disease_DB>GLL020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gallbladder_disease?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Enteropathica</Disease_Name>
      <Disease_Detail>Enteropathica</Disease_Detail>
      <Disease_DB>ENT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/enteropathica?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anal Fistula</Disease_Name>
      <Disease_Detail>Anal Fistula</Disease_Detail>
      <Disease_DB>ANL022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anal_fistula?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Berylliosis</Disease_Name>
      <Disease_Detail>Berylliosis</Disease_Detail>
      <Disease_DB>BRY001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/berylliosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pasteurellosis</Disease_Name>
      <Disease_Detail>Pasteurellosis</Disease_Detail>
      <Disease_DB>PST010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pasteurellosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Immunotactoid Glomerulopathy</Disease_Name>
      <Disease_Detail>Immunotactoid Glomerulopathy</Disease_Detail>
      <Disease_DB>IMM053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/immunotactoid_glomerulopathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoid Nephrosis</Disease_Name>
      <Disease_Detail>Lipoid Nephrosis</Disease_Detail>
      <Disease_DB>LPD004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoid_nephrosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Metabolic Syndrome X</Disease_Name>
      <Disease_Detail>Metabolic Syndrome X</Disease_Detail>
      <Disease_DB>MTB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/metabolic_syndrome_x?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neonatal Stroke</Disease_Name>
      <Disease_Detail>Neonatal Stroke</Disease_Detail>
      <Disease_DB>NNT024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neonatal_stroke?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glomerulonephritis</Disease_Name>
      <Disease_Detail>Glomerulonephritis</Disease_Detail>
      <Disease_DB>GLM007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glomerulonephritis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Liver Disease</Disease_Name>
      <Disease_Detail>Liver Disease</Disease_Detail>
      <Disease_DB>LVR013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liver_disease?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Capillary Leak Syndrome</Disease_Name>
      <Disease_Detail>Capillary Leak Syndrome</Disease_Detail>
      <Disease_DB>CPL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/capillary_leak_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Common Cold</Disease_Name>
      <Disease_Detail>Common Cold</Disease_Detail>
      <Disease_DB>CMM005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/common_cold?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Pyelonephritis</Disease_Name>
      <Disease_Detail>Chronic Pyelonephritis</Disease_Detail>
      <Disease_DB>CHR098</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_pyelonephritis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pericardial Effusion</Disease_Name>
      <Disease_Detail>Pericardial Effusion</Disease_Detail>
      <Disease_DB>PRC012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pericardial_effusion?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bronchiolitis Obliterans Organizing Pneumonia</Disease_Name>
      <Disease_Detail>Bronchiolitis</Disease_Detail>
      <Disease_DB>BRN013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bronchiolitis_obliterans_organizing_pneumonia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Hepatic Fibrosis</Disease_Name>
      <Disease_Detail>Congenital Hepatic Fibrosis</Disease_Detail>
      <Disease_DB>CNG048</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_hepatic_fibrosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vascular Disease</Disease_Name>
      <Disease_Detail>Vascular Disease</Disease_Detail>
      <Disease_DB>VSC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vascular_disease?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatopulmonary Syndrome</Disease_Name>
      <Disease_Detail>Hepatopulmonary Syndrome</Disease_Detail>
      <Disease_DB>HPT009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatopulmonary_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cap Polyposis</Disease_Name>
      <Disease_Detail>Cap Polyposis</Disease_Detail>
      <Disease_DB>CPP003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cap_polyposis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatic Tuberculosis</Disease_Name>
      <Disease_Detail>Hepatic Tuberculosis</Disease_Detail>
      <Disease_DB>HPT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatic_tuberculosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lymphatic System Disease</Disease_Name>
      <Disease_Detail>Lymphatic System Disease</Disease_Detail>
      <Disease_DB>LYM024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lymphatic_system_disease?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoproteinemia, Hypercatabolic</Disease_Name>
      <Disease_Detail>Hypoproteinemia, Hypercatabolic</Disease_Detail>
      <Disease_DB>HYP281</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoproteinemia_hypercatabolic?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysphagia</Disease_Name>
      <Disease_Detail>Dysphagia</Disease_Detail>
      <Disease_DB>DYS073</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysphagia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Yellow Nail Syndrome</Disease_Name>
      <Disease_Detail>Yellow Nail Syndrome</Disease_Detail>
      <Disease_DB>YLL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/yellow_nail_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Nephrotic Syndrome</Disease_Name>
      <Disease_Detail>Nephrotic Syndrome</Disease_Detail>
      <Disease_DB>NPH012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/nephrotic_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Choledocholithiasis</Disease_Name>
      <Disease_Detail>Choledocholithiasis</Disease_Detail>
      <Disease_DB>CHL039</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/choledocholithiasis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Renal Hypertension</Disease_Name>
      <Disease_Detail>Renal Hypertension</Disease_Detail>
      <Disease_DB>RNL015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/renal_hypertension?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Immune Hydrops Fetalis</Disease_Name>
      <Disease_Detail>Immune Hydrops Fetalis</Disease_Detail>
      <Disease_DB>IMM039</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/immune_hydrops_fetalis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypersensitivity Reaction Type Iii Disease</Disease_Name>
      <Disease_Detail>Hypersensitivity Reaction Type Iii Disease</Disease_Detail>
      <Disease_DB>HYP072</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypersensitivity_reaction_type_iii_disease?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysalbuminemic Hyperthyroxinemia</Disease_Name>
      <Disease_Detail>Dysalbuminemic Hyperthyroxinemia</Disease_Detail>
      <Disease_DB>DYS070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysalbuminemic_hyperthyroxinemia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Diarrhea</Disease_Name>
      <Disease_Detail>Acute Diarrhea</Disease_Detail>
      <Disease_DB>ACT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_diarrhea?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Abdominal Tuberculosis</Disease_Name>
      <Disease_Detail>Abdominal Tuberculosis</Disease_Detail>
      <Disease_DB>ABD004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/abdominal_tuberculosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Choanal Atresia</Disease_Name>
      <Disease_Detail>Choanal Atresia</Disease_Detail>
      <Disease_DB>CHN005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/choanal_atresia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kernicterus</Disease_Name>
      <Disease_Detail>Kernicterus</Disease_Detail>
      <Disease_DB>KRN004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kernicterus?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Polyradiculoneuropathy</Disease_Name>
      <Disease_Detail>Polyradiculoneuropathy</Disease_Detail>
      <Disease_DB>PLY020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/polyradiculoneuropathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lead Poisoning</Disease_Name>
      <Disease_Detail>Lead Poisoning</Disease_Detail>
      <Disease_DB>LDP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lead_poisoning?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatorenal Syndrome</Disease_Name>
      <Disease_Detail>Hepatorenal Syndrome</Disease_Detail>
      <Disease_DB>HPT014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatorenal_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysfibrinogenemia</Disease_Name>
      <Disease_Detail>Dysfibrinogenemia</Disease_Detail>
      <Disease_DB>DYS026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysfibrinogenemia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Proteinuria</Disease_Name>
      <Disease_Detail>Proteinuria</Disease_Detail>
      <Disease_DB>PRT039</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/proteinuria?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pulmonary Arteriovenous Malformation</Disease_Name>
      <Disease_Detail>Pulmonary Arteriovenous Malformation</Disease_Detail>
      <Disease_DB>PLM052</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pulmonary_arteriovenous_malformation?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hypertension</Disease_Name>
      <Disease_Detail>Familial Hypertension</Disease_Detail>
      <Disease_DB>FML187</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hypertension?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Generalized Exanthematous Pustulosis</Disease_Name>
      <Disease_Detail>Acute Generalized Exanthematous Pustulosis</Disease_Detail>
      <Disease_DB>ACT167</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_generalized_exanthematous_pustulosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chylous Ascites</Disease_Name>
      <Disease_Detail>Chylous Ascites</Disease_Detail>
      <Disease_DB>CHY006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chylous_ascites?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tuberculosis</Disease_Name>
      <Disease_Detail>Tuberculosis</Disease_Detail>
      <Disease_DB>TBR010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tuberculosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acrodermatitis Enteropathica</Disease_Name>
      <Disease_Detail>Acrodermatitis Enteropathica</Disease_Detail>
      <Disease_DB>ACR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acrodermatitis_enteropathica?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Hyperstimulation Syndrome</Disease_Name>
      <Disease_Detail>Ovarian Disease</Disease_Detail>
      <Disease_DB>OVR029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_hyperstimulation_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anuria</Disease_Name>
      <Disease_Detail>Anuria</Disease_Detail>
      <Disease_DB>ANR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anuria?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertension</Disease_Name>
      <Disease_Detail>Hypertension</Disease_Detail>
      <Disease_DB>HYP075</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertension?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Phenytoin Toxicity</Disease_Name>
      <Disease_Detail>Phenytoin Toxicity</Disease_Detail>
      <Disease_DB>PHN011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/phenytoin_toxicity?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Legionnaires' Disease</Disease_Name>
      <Disease_Detail>Legionnaires' Disease</Disease_Detail>
      <Disease_DB>LGN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/legionnaires_disease?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatitis B</Disease_Name>
      <Disease_Detail>Hepatitis B</Disease_Detail>
      <Disease_DB>HPT016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatitis_b?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Marasmus</Disease_Name>
      <Disease_Detail>Marasmus</Disease_Detail>
      <Disease_DB>MRS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/marasmus?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertensive Retinopathy</Disease_Name>
      <Disease_Detail>Hypertensive Retinopathy</Disease_Detail>
      <Disease_DB>HYP008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertensive_retinopathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Extrinsic Allergic Alveolitis</Disease_Name>
      <Disease_Detail>Extrinsic Allergic Alveolitis</Disease_Detail>
      <Disease_DB>EXT034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/extrinsic_allergic_alveolitis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cronkhite-Canada Syndrome</Disease_Name>
      <Disease_Detail>Cronkhite-Canada Syndrome</Disease_Detail>
      <Disease_DB>CRN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cronkhite_canada_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glomerulosclerosis</Disease_Name>
      <Disease_Detail>Glomerulosclerosis</Disease_Detail>
      <Disease_DB>GLM011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glomerulosclerosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Peptic Ulcer Perforation</Disease_Name>
      <Disease_Detail>Peptic Ulcer Perforation</Disease_Detail>
      <Disease_DB>PPT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/peptic_ulcer_perforation?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Surfactant Dysfunction</Disease_Name>
      <Disease_Detail>Surfactant Dysfunction</Disease_Detail>
      <Disease_DB>SRF006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/surfactant_dysfunction?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hydrops Fetalis</Disease_Name>
      <Disease_Detail>Hydrops Fetalis</Disease_Detail>
      <Disease_DB>HYD012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hydrops_fetalis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Syndrome of Inappropriate Antidiuretic Hormone</Disease_Name>
      <Disease_Detail>Syndrome of Inappropriate Antidiuretic Hormone</Disease_Detail>
      <Disease_DB>SYN046</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/syndrome_of_inappropriate_antidiuretic_hormone?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acrodermatitis</Disease_Name>
      <Disease_Detail>Acrodermatitis</Disease_Detail>
      <Disease_DB>ACR005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acrodermatitis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Protein-Losing Enteropathy</Disease_Name>
      <Disease_Detail>Protein-Losing Enteropathy</Disease_Detail>
      <Disease_DB>PRT019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/protein_losing_enteropathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amyloidosis, Secondary</Disease_Name>
      <Disease_Detail>Amyloidosis</Disease_Detail>
      <Disease_DB>AMY053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amyloidosis_secondary?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Constrictive Pericarditis</Disease_Name>
      <Disease_Detail>Constrictive Pericarditis</Disease_Detail>
      <Disease_DB>CNS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/constrictive_pericarditis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Euthyroid Sick Syndrome</Disease_Name>
      <Disease_Detail>Euthyroid Sick Syndrome</Disease_Detail>
      <Disease_DB>ETH004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/euthyroid_sick_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pellagra</Disease_Name>
      <Disease_Detail>Pellagra</Disease_Detail>
      <Disease_DB>PLL002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pellagra?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Analbuminemia</Disease_Name>
      <Disease_Detail>Analbuminemia</Disease_Detail>
      <Disease_DB>ANL018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/analbuminemia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoprotein Glomerulopathy</Disease_Name>
      <Disease_Detail>Lipoprotein Glomerulopathy</Disease_Detail>
      <Disease_DB>LPP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoprotein_glomerulopathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bronchiolitis</Disease_Name>
      <Disease_Detail>Bronchiolitis</Disease_Detail>
      <Disease_DB>BRN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bronchiolitis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tricuspid Atresia</Disease_Name>
      <Disease_Detail>Tricuspid Atresia</Disease_Detail>
      <Disease_DB>TRC062</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tricuspid_atresia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intestinal Obstruction</Disease_Name>
      <Disease_Detail>Intestinal Obstruction</Disease_Detail>
      <Disease_DB>INT070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intestinal_obstruction?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Visceral Myopathy</Disease_Name>
      <Disease_Detail>Visceral Myopathy</Disease_Detail>
      <Disease_DB>VSC044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/visceral_myopathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Miliary Tuberculosis</Disease_Name>
      <Disease_Detail>Miliary Tuberculosis</Disease_Detail>
      <Disease_DB>MLR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/miliary_tuberculosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Scurvy</Disease_Name>
      <Disease_Detail>Scurvy</Disease_Detail>
      <Disease_DB>SCR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scurvy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Compartment Syndrome</Disease_Name>
      <Disease_Detail>Compartment Syndrome</Disease_Detail>
      <Disease_DB>CMP008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/compartment_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Essential Hypertension</Disease_Name>
      <Disease_Detail>Essential Hypertension</Disease_Detail>
      <Disease_DB>ESS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/essential_hypertension?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Decubitus Ulcer</Disease_Name>
      <Disease_Detail>Decubitus Ulcer</Disease_Detail>
      <Disease_DB>DCB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/decubitus_ulcer?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperthyroxinemia</Disease_Name>
      <Disease_Detail>Hyperthyroxinemia</Disease_Detail>
      <Disease_DB>HYP029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperthyroxinemia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertensive Nephropathy</Disease_Name>
      <Disease_Detail>Hypertensive Nephropathy</Disease_Detail>
      <Disease_DB>HYP114</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertensive_nephropathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Kidney Failure</Disease_Name>
      <Disease_Detail>Acute Kidney Failure</Disease_Detail>
      <Disease_DB>ACT071</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_kidney_failure?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Systemic Capillary Leak Syndrome</Disease_Name>
      <Disease_Detail>Systemic Capillary Leak Syndrome</Disease_Detail>
      <Disease_DB>SYS007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/systemic_capillary_leak_syndrome?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pure Red-Cell Aplasia</Disease_Name>
      <Disease_Detail>Pure Red-Cell Aplasia</Disease_Detail>
      <Disease_DB>PRR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pure_red_cell_aplasia?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Poststreptococcal Glomerulonephritis</Disease_Name>
      <Disease_Detail>Acute Poststreptococcal Glomerulonephritis</Disease_Detail>
      <Disease_DB>ACT040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_poststreptococcal_glomerulonephritis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Eosinophilic Gastroenteritis</Disease_Name>
      <Disease_Detail>Eosinophilic Gastroenteritis</Disease_Detail>
      <Disease_DB>ESN005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/eosinophilic_gastroenteritis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Liver Cirrhosis</Disease_Name>
      <Disease_Detail>Liver Cirrhosis</Disease_Detail>
      <Disease_DB>LVR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liver_cirrhosis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</Disease_Name>
      <Disease_Detail>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</Disease_Detail>
      <Disease_DB>CHR070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_inflammatory_demyelinating_polyradiculoneuropathy?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intussusception</Disease_Name>
      <Disease_Detail>Intussusception</Disease_Detail>
      <Disease_DB>INT051</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intussusception?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amitriptyline Toxicity</Disease_Name>
      <Disease_Detail>Amitriptyline Toxicity</Disease_Detail>
      <Disease_DB>AMT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amitriptyline_toxicity?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Calciphylaxis</Disease_Name>
      <Disease_Detail>Calciphylaxis</Disease_Detail>
      <Disease_DB>CLC001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/calciphylaxis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fibrocalculous Pancreatic Diabetes</Disease_Name>
      <Disease_Detail>Fibrocalculous Pancreatic Diabetes</Disease_Detail>
      <Disease_DB>FBR063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fibrocalculous_pancreatic_diabetes?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Strongyloidiasis</Disease_Name>
      <Disease_Detail>Strongyloidiasis</Disease_Detail>
      <Disease_DB>STR008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/strongyloidiasis?search=ALB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arteriovenous Malformation</Disease_Name>
      <Disease_Detail>Arteriovenous Malformation</Disease_Detail>
      <Disease_DB>ART005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arteriovenous_malformation?search=ALB#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Solution structure of the complex between immunoglobulin IgA1 and human serum albumin</PDB_Title>
      <PDB_ID>2ESG</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ESG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Purification, properties and extended solution structure of the complex formed between human immunoglobulin A1 and human serum albumin by scattering and ultracentrifugation</PubMed_Title>
      <Author>Almogren A, et al.</Author>
      <Journal>J Mol Biol. 2006 Feb 17;356(2):413-31. Epub 2005 Dec 7.</Journal>
      <PubMed_ID>16376934</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH FUSIDIC ACID</PDB_Title>
      <PDB_ID>2VUF</PDB_ID>
      <Resolution>3.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VUF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>FUSIDIC ACID</Ligand_Name>
      <PubMed_Title>Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-Ixalpha</PubMed_Title>
      <Author>Zunszain PA, et al.</Author>
      <Journal>J Mol Biol. 2008 Aug 29;381(2):394-406. Epub 2008 Jun 12.</Journal>
      <PubMed_ID>18602119</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of domain 3 from human serum albumin complexed to an anti-apoptotic ligand directed against Bcl-xL and Bcl-2</PDB_Title>
      <PDB_ID>1YSX</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YSX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-({2-[(2,4-DIMETHYLPHENYL)SULFANYL]ETHYL}AMINO)- N-[(4'-FLUORO-1,1'-BIPHENYL-4
-YL)CARBONYL]- 3-NITROBENZENESULFONAMIDE</Ligand_Name>
      <PubMed_Title>An inhibitor of Bcl-2 family proteins induces regression of solid tumours</PubMed_Title>
      <Author>Oltersdorf T, et al.</Author>
      <Journal>Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15</Journal>
      <PubMed_ID>15902208</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH HEXADECANOIC ACID (PALMITIC ACID)</PDB_Title>
      <PDB_ID>1E7H</PDB_ID>
      <Resolution>2.43</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PALMITIC ACID</Ligand_Name>
      <PubMed_Title>Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Mol Biol. 2000 Nov 10;303(5):721-32.</Journal>
      <PubMed_ID>11061971</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH DIFLUNISAL</PDB_Title>
      <PDB_ID>2BXE</PDB_ID>
      <Resolution>2.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXE</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01140129</ASD_Ligand>
      <Ligand_Name>5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169018</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN IN A COMPLEX WITH MYRISTIC ACID AND TRI-IODOBENZOIC ACID</PDB_Title>
      <PDB_ID>1BKE</PDB_ID>
      <Resolution>3.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BKE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2,3,5-TRIIODOBENZOIC ACID$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites</PubMed_Title>
      <Author>Curry S, et al.</Author>
      <Journal>Nat Struct Biol. 1998 Sep;5(9):827-35.</Journal>
      <PubMed_ID>9731778</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE GENERAL ANESTHETIC HALOTHANE</PDB_Title>
      <PDB_ID>1E7C</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7C</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670007</ASD_Ligand>
      <Ligand_Name>2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Biol Chem. 2000 Dec 8;275(49):38731-11.</Journal>
      <PubMed_ID>10940306</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH CIS-5,8,11,14-EICOSATETRAENOIC ACID (ARACHIDONIC ACID)</PDB_Title>
      <PDB_ID>1GNJ</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GNJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ARACHIDONIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>J Mol Biol. 2001 Dec 14;314(5):955-60</Journal>
      <PubMed_ID>11743713</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND PHENYLBUTAZONE</PDB_Title>
      <PDB_ID>2BXP</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169029</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE S-(-) ENANTIOMER OF WARFARIN</PDB_Title>
      <PDB_ID>1HA2</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HA2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$4-HYDROXY-3-[(1S,3S)-3-HYDROXY-1-PHENYLBUTYL]- 2H-CHROMEN-2-ONE</Ligand_Name>
      <PubMed_Title>Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>J Biol Chem. 2001 Jun 22;276(25):22804-9. Epub 2001 Apr 3.</Journal>
      <PubMed_ID>11285263</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH THE GENERAL ANESTHETIC PROPOFOL</PDB_Title>
      <PDB_ID>1E7A</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2,6-BIS(1-METHYLETHYL)PHENOL</Ligand_Name>
      <PubMed_Title>Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Biol Chem. 2000 Dec 8;275(49):38731-9.</Journal>
      <PubMed_ID>10940304</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH PHENYLBUTAZONE</PDB_Title>
      <PDB_ID>2BXC</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXC</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670015</ASD_Ligand>
      <Ligand_Name>4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169016</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) AND MYRISTIC ACID (TETRADECANOIC ACID)</PDB_Title>
      <PDB_ID>1HK5</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HK5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3,5,3',5'-TETRAIODO-L-THYRONINE$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6440-5. Epub 2003 May 16.</Journal>
      <PubMed_ID>12743365</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH HEME</PDB_Title>
      <PDB_ID>1N5U</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1N5U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PROTOPORPHYRIN IX CONTAINING FE$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>The atomic structure of human methemalbumin at 1.9 A</PubMed_Title>
      <Author>Wardell M, et al.</Author>
      <Journal>Biochem Biophys Res Commun. 2002 Mar 8;291(4):813-9.</Journal>
      <PubMed_ID>11866438</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)</PDB_Title>
      <PDB_ID>1HK1</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HK1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3,5,3',5'-TETRAIODO-L-THYRONINE</Ligand_Name>
      <PubMed_Title>Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6440-5. Epub 2003 May 12.</Journal>
      <PubMed_ID>12743361</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE, PHENYLBUTAZONE AND INDOMETHACIN</PDB_Title>
      <PDB_ID>2BXQ</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>INDOMETHACIN$MYRISTIC ACID$4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169030</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH THE GENERAL ANESTHETIC HALOTHANE</PDB_Title>
      <PDB_ID>1E7B</PDB_ID>
      <Resolution>2.38</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7B</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670007</ASD_Ligand>
      <Ligand_Name>2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE</Ligand_Name>
      <PubMed_Title>Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Biol Chem. 2000 Dec 8;275(49):38731-10.</Journal>
      <PubMed_ID>10940305</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN SERUM ALBUMIN WITH S-NAPROXEN AND THE GA MODULE</PDB_Title>
      <PDB_ID>2VDB</PDB_ID>
      <Resolution>2.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VDB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>DECANOIC ACID$(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid</Ligand_Name>
      <PubMed_Title>Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module</PubMed_Title>
      <Author>Lejon S, et al.</Author>
      <Journal>Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Feb 1;64(Pt 2):64-9. Epub 2008 Jan 18.</Journal>
      <PubMed_ID>18259051</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID</PDB_Title>
      <PDB_ID>1BJ5</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BJ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites</PubMed_Title>
      <Author>Curry S, et al.</Author>
      <Journal>Nat Struct Biol. 1998 Sep;5(9):827-36.</Journal>
      <PubMed_ID>9731779</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN</PDB_Title>
      <PDB_ID>1E78</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E78</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Biol Chem. 2000 Dec 8;275(49):38731-8.</Journal>
      <PubMed_ID>10940303</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human serum albumin complexed with Myristic acid and lysophosphatidylethanolamine</PDB_Title>
      <PDB_ID>3CX9</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CX9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(2S)-3-{[(R)-(2-aminoethoxy)(hydroxy)phosphoryl]oxy}- 2-hydroxypropyl hexadecanoate$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of transport of lysophospholipids by human serum albumin</PubMed_Title>
      <Author>Guo S, et al.</Author>
      <Journal>Biochem J. 2009 Sep 14;423(1):23-30.</Journal>
      <PubMed_ID>19601929</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY STUDY OF RECOMBINANT HUMAN SERUM ALBUMIN. PHASES DETERMINED BY MOLECULAR REPLACEMENT METHOD, USING LOW RESOLUTION STRUCTURE MODEL OF TETRAGONAL FORM OF HUMAN SERUM ALBUMIN</PDB_Title>
      <PDB_ID>1UOR</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UOR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Atomic structure and chemistry of human serum albumin</PubMed_Title>
      <Author>He XM, et al.</Author>
      <Journal>Nature. 1992 Jul 16;358(6383):209-15.</Journal>
      <PubMed_ID>1630489</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human serum albumin complexed with Lidocaine</PDB_Title>
      <PDB_ID>3JQZ</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JQZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-(diethylamino)-N-(2,6-dimethylphenyl)ethanamide</Ligand_Name>
      <PubMed_Title>Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin.</PubMed_Title>
      <Author>Hein KL, et al.</Author>
      <Journal>J Struct Biol. 2010 Mar 27.</Journal>
      <PubMed_ID>20347991</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the GA module complexed with human serum albumin</PDB_Title>
      <PDB_ID>1TF0</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TF0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>CITRIC ACID$DECANOIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin.</PubMed_Title>
      <Author>Lejon S, et al.</Author>
      <Journal>J Biol Chem. 2004 Oct 8;279(41):42924-8. Epub 2004 Jul 21.</Journal>
      <PubMed_ID>15269208</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE, AZAPROPAZONE AND INDOMETHACIN</PDB_Title>
      <PDB_ID>2BXK</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>AZAPROPAZONE$INDOMETHACIN$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169023</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN</PDB_Title>
      <PDB_ID>1BM0</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BM0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human serum albumin at 2.5 A resolution</PubMed_Title>
      <Author>Sugio S, et al.</Author>
      <Journal>Protein Eng. 1999 Jun;12(6):439-46.</Journal>
      <PubMed_ID>10388840</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND IODIPAMIDE</PDB_Title>
      <PDB_ID>2BXN</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]- 2,4,6-TRIIODO-BENZOIC ACID$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169027</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN MUTANT R218P COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)</PDB_Title>
      <PDB_ID>1HK3</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HK3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3,5,3',5'-TETRAIODO-L-THYRONINE</Ligand_Name>
      <PubMed_Title>Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6440-5. Epub 2003 May 14.</Journal>
      <PubMed_ID>12743363</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPANOIC ACID (CMPF)</PDB_Title>
      <PDB_ID>2BXA</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXA</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670013</ASD_Ligand>
      <Ligand_Name>3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169014</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH AZAPROPAZONE</PDB_Title>
      <PDB_ID>2BX8</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BX8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670012</ASD_Ligand>
      <Ligand_Name>AZAPROPAZONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169013</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH 4Z,15E-BILIRUBIN-IX-ALPHA</PDB_Title>
      <PDB_ID>2VUE</PDB_ID>
      <Resolution>2.42</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VUE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>BILIVERDINE IX ALPHA</Ligand_Name>
      <PubMed_Title>Crystallographic analysis of human serum albumin complexed with 4Z,16E-bilirubin-Ixalpha</PubMed_Title>
      <Author>Zunszain PA, et al.</Author>
      <Journal>J Mol Biol. 2008 Aug 29;381(2):394-406. Epub 2008 Jun 13.</Journal>
      <PubMed_ID>18602120</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC ACID) HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID</PDB_Title>
      <PDB_ID>1E7G</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Mol Biol. 2000 Nov 10;303(5):721-32.</Journal>
      <PubMed_ID>11061974</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE R-(+) ENANTIOMER OF WARFARIN</PDB_Title>
      <PDB_ID>1H9Z</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1H9Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$4-HYDROXY-3-[(1S,3R)-3-HYDROXY-1-PHENYLBUTYL]- 2H-CHROMEN-2-ONE</Ligand_Name>
      <PubMed_Title>Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>J Biol Chem. 2001 Jun 22;276(25):22804-9. Epub 2001 Apr 2.</Journal>
      <PubMed_ID>11285262</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH IBUPROFEN</PDB_Title>
      <PDB_ID>2BXG</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXG</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670006</ASD_Ligand>
      <Ligand_Name>IBUPROFEN</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169020</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human serum albumin in complex with compound 1</PDB_Title>
      <PDB_ID>3LU6</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LU6</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670019</ASD_Ligand>
      <PubMed_Title>A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions</PubMed_Title>
      <Author>Buttar, D., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2010)18:7486-7496</Journal>
      <PubMed_ID>20869876</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH DIAZEPAM</PDB_Title>
      <PDB_ID>2BXF</PDB_ID>
      <Resolution>2.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>7-CHLORO-1-METHYL-5-PHENYL-1,3-DIHYDRO-2H- 1,4-BENZODIAZEPIN-2-ONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169019</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND OXYPHENBUTAZONE</PDB_Title>
      <PDB_ID>2BXO</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYLPYRAZOLIDINE- 3,5-DIONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169028</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Serum albumin with bound Sulfate</PDB_Title>
      <PDB_ID>3JRY</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JRY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin.</PubMed_Title>
      <Author>Hein KL, et al.</Author>
      <Journal>J Struct Biol. 2010 Mar 27.</Journal>
      <PubMed_ID>20347992</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human serum albumin complexed with myristate and AZT</PDB_Title>
      <PDB_ID>3B9L</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B9L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3'-azido-3'-deoxythymidine$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography</PubMed_Title>
      <Author>Zhu L, et al.</Author>
      <Journal>J Struct Biol. 2008 Apr;162(1):40-9. Epub 2007 Dec 28.</Journal>
      <PubMed_ID>18258455</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH CIS-9-OCTADECENOIC ACID (OLEIC ACID)</PDB_Title>
      <PDB_ID>1GNI</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GNI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>OLEIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>J Mol Biol. 2001 Dec 14;314(5):955-60</Journal>
      <PubMed_ID>11743713</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human serum albumin complexed with myristate and salicylic acid</PDB_Title>
      <PDB_ID>2I30</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I30</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$2-HYDROXYBENZOIC ACID</Ligand_Name>
      <PubMed_Title>Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin</PubMed_Title>
      <Author>Yang F, et al.</Author>
      <Journal>J Struct Biol. 2007 Feb;157(2):348-55. Epub 2006 Sep 9</Journal>
      <PubMed_ID>17067818</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN</PDB_Title>
      <PDB_ID>1AO6</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AO6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human serum albumin at 2.5 A resolution</PubMed_Title>
      <Author>Sugio S, et al.</Author>
      <Journal>Protein Eng. 1999 Jun;12(6):439-46.</Journal>
      <PubMed_ID>10388840</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH DECANOIC ACID (CAPRIC ACID)</PDB_Title>
      <PDB_ID>1E7E</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>DECANOIC ACID</Ligand_Name>
      <PubMed_Title>Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Mol Biol. 2000 Nov 10;303(5):721-32.</Journal>
      <PubMed_ID>11061972</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND INDOMETHACIN</PDB_Title>
      <PDB_ID>2BXM</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>INDOMETHACIN$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169026</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of Human serum albumin complexed with delta 12-prostaglandin J2</PDB_Title>
      <PDB_ID>3A73</PDB_ID>
      <Resolution>2.19</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A73</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$(5Z,12Z,15S)-15-hydroxy-11-oxoprosta-5,9,12- trien-1-oic acid</Ligand_Name>
      <PubMed_Title>Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146.</PubMed_Title>
      <Author>Yamaguchi S, et al.</Author>
      <Journal>J Am Chem Soc. 2010 Jan 20;132(2):824-32.</Journal>
      <PubMed_ID>20014793</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)</PDB_Title>
      <PDB_ID>1HK2</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HK2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3,5,3',5'-TETRAIODO-L-THYRONINE</Ligand_Name>
      <PubMed_Title>Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6440-5. Epub 2003 May 13.</Journal>
      <PubMed_ID>12743362</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH OXYPHENBUTAZONE</PDB_Title>
      <PDB_ID>2BXB</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670014</ASD_Ligand>
      <Ligand_Name>4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYLPYRAZOLIDINE- 3,5-DIONE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169015</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human serum albumin complexed with myristate, 3'-azido-3'-deoxythymidine (AZT) and salicylic acid</PDB_Title>
      <PDB_ID>3B9M</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B9M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3'-azido-3'-deoxythymidine$MYRISTIC ACID$2-HYDROXYBENZOIC ACID</Ligand_Name>
      <PubMed_Title>A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography</PubMed_Title>
      <Author>Zhu L, et al.</Author>
      <Journal>J Struct Biol. 2008 Apr;162(1):40-9. Epub 2007 Dec 28.</Journal>
      <PubMed_ID>18258455</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH DODECANOIC ACID (LAURIC ACID)</PDB_Title>
      <PDB_ID>1E7F</PDB_ID>
      <Resolution>2.43</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>LAURIC ACID</Ligand_Name>
      <PubMed_Title>Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Mol Biol. 2000 Nov 10;303(5):721-32.</Journal>
      <PubMed_ID>11061973</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND 3,5-DIIODOSALICYLIC ACID</PDB_Title>
      <PDB_ID>2BXL</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-HYDROXY-3,5-DIIODO-BENZOIC ACID$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169024</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH WARFARIN</PDB_Title>
      <PDB_ID>2BXD</PDB_ID>
      <Resolution>3.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXD</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670002</ASD_Ligand>
      <Ligand_Name>R-WARFARIN</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169017</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human serum albumin in complex with compound 2</PDB_Title>
      <PDB_ID>3LU7</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LU7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670021</ASD_Ligand>
      <PubMed_Title>A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions</PubMed_Title>
      <Author>Buttar, D., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2010)18:7486-7496</Journal>
      <PubMed_ID>20869876</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC ACID) AND HEMIN</PDB_Title>
      <PDB_ID>1O9X</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1O9X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PROTOPORPHYRIN IX CONTAINING FE $MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Crystal structural analysis of human serum albumin complexed with hemin and fatty acid</PubMed_Title>
      <Author>Zunszain PA, et al.</Author>
      <Journal>BMC Struct Biol. 2003 Jul 7;3:6. Epub 2003 Jul 7.</Journal>
      <PubMed_ID>12846933</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human serum albumin complexed with myristate and aspirin</PDB_Title>
      <PDB_ID>2I2Z</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I2Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MYRISTIC ACID$2-HYDROXYBENZOIC ACID</Ligand_Name>
      <PubMed_Title>Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin</PubMed_Title>
      <Author>Yang F, et al.</Author>
      <Journal>J Struct Biol. 2007 Feb;157(2):348-55. Epub 2006 Sep 9</Journal>
      <PubMed_ID>17067818</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH INDOXYL SULFATE</PDB_Title>
      <PDB_ID>2BXH</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXH</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02670018</ASD_Ligand>
      <Ligand_Name>3-SULFOOXY-1H-INDOLE</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169021</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH OCTADECANOIC ACID (STEARIC ACID)</PDB_Title>
      <PDB_ID>1E7I</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E7I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>STEARIC ACID</Ligand_Name>
      <PubMed_Title>Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin</PubMed_Title>
      <Author>Bhattacharya AA, et al.</Author>
      <Journal>J Mol Biol. 2000 Nov 10;303(5):721-33.</Journal>
      <PubMed_ID>11061975</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) AND MYRISTIC ACID (TETRADECANOIC ACID)</PDB_Title>
      <PDB_ID>1HK4</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HK4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3,5,3',5'-TETRAIODO-L-THYRONINE$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia</PubMed_Title>
      <Author>Petitpas I, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6440-5. Epub 2003 May 15.</Journal>
      <PubMed_ID>12743364</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND AZAPROPAZONE</PDB_Title>
      <PDB_ID>2BXI</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>AZAPROPAZONE$MYRISTIC ACID</Ligand_Name>
      <PubMed_Title>Structural basis of the drug-binding specificity of human serum albumin</PubMed_Title>
      <Author>Ghuman J, et al.</Author>
      <Journal>J Mol Biol. 2005 Oct 14;353(1):38-52.</Journal>
      <PubMed_ID>16169022</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cfb.b.b.b.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/2bxa</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,174,Tyr;site,219,Lys;site,223,Lys;site,238,Trp;site,242,Arg;site,246,Arg;site,266,His;site,281,Arg;site,288,Ile;site,372,Arg;site,407,Glu;site,411,Leu;site,415,Asn;site,434,Arg;site,435,Tyr;site,438,Lys;site,454,Leu;site,457,Val;site,474,Glu;site,509,Arg;site,513,Ser</Site_Detail>
      <Site_Reference>Nicoletti FP, et al. J Am Chem Soc. 2008,130(35):11677-11688.;Ghuman J, et al. J Mol Biol. 2005,353(1):38-52. </Site_Reference>
      <Site_Type>Three allosteric sites</Site_Type>
      <PDB_ID>2BXD;2BXG</PDB_ID>
      <PubMed_ID>18681435;16169013</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00240009</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00820001</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01140129</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670003</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670004</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670005</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02670021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>